Literature DB >> 16476567

Effect of cyclosporin A on the biliary excretion of cholephilic compounds in rats.

Masahiro Akashi1, Atsushi Tanaka, Hajime Takikawa.   

Abstract

Cyclosporin A (CsA) is known to cause cholestasis. CsA is reported to competitively inhibit the transport of the substrates of the bile salt export pump (Bsep), multidrug resistance protein 2 (Mrp2) and P-glycoprotein (P-gp) in the canalicular membrane vesicles. However, the inhibitory effect of CsA on various substrates of the canalicular ATP-dependent transporters in vivo is unknown. Therefore, in the present study, the acute effect of CsA on the biliary excretion of the substrates of Bsep, Mrp2 and P-gp was examined under the same condition. Ten minutes after the intravenous administration of CsA (25mg/kg), the biliary excretion of various bile acids and organic anions and cations was studied. CsA decreased the biliary excretion of tracer amounts of taurocholate, leukotriene C(4), estradiol-17beta-glucuronide, pravastatin, vinblastine and erythromycin. In contrast, the biliary excretion of high doses of taurocholate and sulfobromophthalein was only slightly or not inhibited by CsA. In conclusion, CsA may competitively inhibit biliary excretion of substrates of Bsep, Mrp2 and P-gp also in vivo, and CsA is considered to inhibit bile acid-dependent bile flow by the competitive inhibition of the canalicular transport of bile acids by Bsep.

Entities:  

Year:  2006        PMID: 16476567     DOI: 10.1016/j.hepres.2005.08.013

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  1 in total

1.  Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2?

Authors:  Ryuji Kato; Mami Nishide; Chihiro Kozu; Asuka Iwamoto; Kazuya Urashima; Kaoru Suzuki; Yoshio Ijiri; Tetsuya Hayashi; Kazuhiko Tanaka
Journal:  Eur J Clin Pharmacol       Date:  2009-10-13       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.